on Onco-Innovations Limited (CVE:ONCO)
Onco-Innovations Appoints Dr. John Mackey to Advisory Board
Onco-Innovations Limited has announced the appointment of Dr. John Mackey to its Scientific and Clinical Advisory Board. Dr. Mackey, Professor Emeritus at the University of Alberta, brings vast oncology and clinical trial expertise. His role will aid Onco's translation of research into clinical practice, especially in advancing the PNKP inhibitor program.
Dr. Mackey's experience includes serving as Director of Clinical Trial Unit at Cross Cancer Institute and Executive Director at TRIO. He co-founded Pacylex Pharmaceuticals, involved in Phase II trials, and leads illumiSonics, focusing on molecular histology technology. With 12 patents and over 300 publications, Dr. Mackey's insights will guide Onco's clinical strategies, aiding their mission in cancer research.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Onco-Innovations Limited news